Prevalence of neuropsychiatric adverse events and associated factors among adult patients on Dolutegravir attending Mulago ISS clinic.
Abstract
Introduction: Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor that is
recommended by World Health Organization for use as the preferred first line and second line anti-retroviral
regimen in HIV infected patients. In 2018, Uganda started using DTG-based regimens as the preferred first
line antiretroviral therapy. However, there have been increased concerns regarding the potential
neurotoxicity of DTG. There is limited data in Uganda on the occurrence of neuropsychiatric adverse events
and the associated factors among adult patients who are initiated or switched to a DTG based first line or
second line anti-retroviral regimen.
Objective: This study aimed to determine the prevalence of neuropsychiatric adverse events (NPAEs)
among adult patients on DTG and the factors associated with the occurrence of NPAEs.
Methods: A Cross-sectional study was conducted using questionnaires administered by a trained research
assistant between 15 November 2021 and 15 December 2021. The study included HIV positive patients aged
18 years above who were either initiated or switched to a DTG based antiretroviral therapy (ART) regimen
between 1 January 2018 and 31 October 2021. Data was collected from 892 participants attending Mulago
ISS clinic after informed consent was obtained. Data was collected on age, sex, marital status, disclosure
status, current regimen, duration on ART, concurrent illness, concurrent medications, Year of switch to
DTG, duration on DTG, whether the onset of NPAEs was immediate or delayed, history of alcohol or
smoking use, level of education, report of NPAEs while on DTG, history of NPAE while on previous
regimen. Data was entered into Epidata Version 4.6.0.2 then exported to Stata version 14 for analysis.
Results: Of the 892 adults on DTG attending Mulago ISS clinic, 41.7% (95%CI: 38.5 – 44.9%) experienced
at least one NPAE. DTG duration in years (aPR= 1.21, p = 0.024), disclosure status (aPR= 1.40, p = 0.042),
concurrent medications (aPR= 1.31, p = 0.026), year of switch to DTG and concurrent illness were the
covariates associated with increased occurrence of NPAEs.
xii
Conclusions: The prevalence of NPAEs was found to be higher than that reported by any randomised
clinical trial. About 9.1% of the participants experienced severe to life threatening NPAEs that required
intervention of a health care professional to ensure better tolerability. The high prevalence found requires
that clinicians carryout screening for NPAEs at very visit and reassure the patients in order to maximize the
benefits of long term ART.